同期放化疗治疗食管鳞癌的近期疗效及安全性分析

Short-term efficacy and safety analysis of concurrent chemoradiotherapy f or esophageal squamous cell carcinoma

目的:探讨对食管鳞状细胞癌(鳞癌)患者进行同期放化疗的近期疗效及安全性。方法:选取连云港市第二人民医院肿瘤科收治的90例食管鳞癌患者作为研究对象。随机将其分为对照组和观察组。对对照组患者进行单纯放疗,对观察组患者进行同期放化疗,然后比较两组患者的近期疗效、不良反应的发生率、1年内的总生存率及无进展生存率。结果:观察组患者治疗的总有效率高于对照组患者,P<0.05。治疗后,观察组患者急性放射性食管炎的发生率高于对照组患者,P<0.05。治疗后,两组患者急性放射性肺炎、放射性气道损伤、放射性肺纤维化、胸腔积液/心包积液、胃肠道反应、血常规指标异常的发生率相比,P>0.05。治疗后的1年内,观察组患者的总生存率和无进展生存率均高于对照组患者,P<0.05。结论:对食管鳞癌患者进行同期放化疗的近期疗效较好,能提高其总生存率和无进展生存率,且不会增加其急性放射性肺炎、放射性气道损伤、胃肠道反应等不良反应的发生率,但会增加其急性放射性食管炎的发生风险。

Objective:To investigate the short-term efficacy and safety of concurrent chemoradiotherapy in patients with esophageal squamous cell carcinoma(SQUamous cell carcinoma).Methods:90 patients with esophageal squamous cell carcinoma admitted to the Second People’s Hospital of Lianyungang city were selected as the research object.They were randomly divided into control group and observation group.Patients in the control group were treated with radiotherapy alone,and patients in the observation group were treated with concurrent radiotherapy and chemotherapy.The short-term efficacy,incidence of adverse reactions,1-year overall survival rate and progression-free survival rate of patients in the two groups were compared.Results:The total effective rate of observation group was higher than control group,P<0.05.After treatment,the incidence of acute radioactive esophagitis in observation group was higher than that in control group,P<0.05.After treatment,the incidence of acute radioactive pneumonia,radioactive airway injury,radioactive pulmonary fibrosis,pleural effusion/pericardial effusion,gastrointestinal reaction and abnormal blood routine indexes in 2 groups were compared,P>0.05.Within 1 year after treatment,the overall survival rate and progression-free survival rate of patients in the observation group were higher than those in the control group,P<0.05.Conclusion:Concurrent chemoradiotherapy has a good short-term efficacy in patients with esophageal squamous cell carcinoma,which can im prove the overall survival rate and progression-free survival rate,and does not increase the incidence of acute radioactive pneumonia,radioactive airway injury,gastrointestinal reactions and other adverse reactions,but will increase the risk of acute radioactive esophagitis.